These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 32667636)

  • 21. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
    Kane JM; McEvoy JP; Correll CU; Llorca PM
    CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
    Mustafa S; Bougie J; Miguelez M; Clerzius G; Rampakakis E; Proulx J; Malla A
    BMC Psychiatry; 2019 Apr; 19(1):114. PubMed ID: 30991969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.
    Olivares JM; González-Pinto A; Páramo M;
    Eur Psychiatry; 2021 Apr; 64(1):e40. PubMed ID: 33840396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.
    Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
    Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
    Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
    Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
    J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
    Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
    CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
    Lauriello J; Weiden PJ; Gleeson CD; Shah A; Boulanger L; Jariwala-Parikh K; Hedgeman E; O'Sullivan AK
    CNS Drugs; 2021 Oct; 35(10):1123-1135. PubMed ID: 34546558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
    Huang CY; Fang SC; Shao YJ
    JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists.
    Fagiolini A; Alfonsi E; Amodeo G; Cenci M; Di Lella M; Farinella F; Ferraiuolo F; Fraguas D; Loparco N; Gutierrez-Rojas L; Mignone ML; Pataracchia G; Pillai G; Russo F; Sanchez-Gistau V; Spinogatti F; Toscano M; Villari V; De Filippis S
    Expert Opin Drug Saf; 2016; 15(4):449-55. PubMed ID: 26886162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
    Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
    Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.